Trials / Unknown
UnknownNCT04172480
HUSH Restriction in HIV Infected Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- ANRS, Emerging Infectious Diseases · Other Government
- Sex
- All
- Age
- 15 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
HIV eradication faces a major obstacle that is viral persistence in latent reservoir cells despite antiretroviral therapy. Epigenetic repression plays a central role in viral transgene latency and several epigenetic regulators have been involved in this process. Among them, the "Human Silencing Hub" or HUSH complex, composed of Tasor, MPP8 and periphilin, has been shown to recruit the H3K9me3 methyltransferase "SET domain bifurcated 1" (SETDB1) and is therefore responsible for genes' epigenetic repression. Our recent results highlight the ability of Vpx from HIV-2/SIVsmm to counteract HUSH and to reactivate latent viruses in a latency model. We propose here to study HUSH activity along pathogenesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood sampling | Peripheral blood sampling on EDTA |
Timeline
- Start date
- 2019-10-01
- Primary completion
- 2023-09-30
- Completion
- 2023-09-30
- First posted
- 2019-11-21
- Last updated
- 2021-12-20
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04172480. Inclusion in this directory is not an endorsement.